<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731820</url>
  </required_header>
  <id_info>
    <org_study_id>6013_IOR</org_study_id>
    <secondary_id>1676</secondary_id>
    <nct_id>NCT02731820</nct_id>
  </id_info>
  <brief_title>Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia</brief_title>
  <acronym>ACAROS</acronym>
  <official_title>Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia. A Randomized, Placebo-controlled, Double Blind Investigation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether the use of alkali compounds, i.e.
      potassium citrate (K3C6H5O7, hereinafter KCitr) is effective in preventing the progression of
      osteopenia.

      A randomized clinical trial (RCT, placebo-controlled, double-blind) has been planned to
      evaluate the effect of the daily administration of KCitr (3 g/die, K 30 mEq).

      The efficacy will be evaluated by comparing the circulating levels of bone turnover markers
      at the baseline and after the treatment (3, 6 months).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bone tissue carries out some of the important metabolic functions, including the regulation
      of acid-base balance. In order to buffer the systemic acidosis, the skeleton acts as a &quot;ion
      exchange column&quot; modifying the composition of the mineral portion, i.e. the hydroxyapatite.
      There is a linear correlation between elimination of calcium and acidosis: the higher is the
      acidosis, the higher will be the loss of calcium from bones. In vitro experiments showed that
      acidosis also directly influences the cellular component of bone by increasing the osteoclast
      activity and inhibiting the production of the mineralized matrix by osteoblast. Since the low
      pH is a risk factor that accelerates the bone loss, the use of alkalizing compounds could
      prevent the osteopenia or support the conventional therapy of the osteoporosis.

      KCitr is an alkaline compound which may be used in metabolic acidosis. Potassium is an
      alkaline metal that plays a pivotal role in the function of all living cells. Citric acid is
      a key molecule of the Krebs cycle, and it is abundant in bone where exhibits a stabilizing
      function. Although clinical data regarding the KCitr effectiveness on calcium metabolism are
      encouraging, it is still unclear whether the beneficial effects are due exclusively to the
      buffering function or whether KCitr may affect the bone cells activity. The purpose of this
      study is to evaluate the effects of KCitr on bone metabolism. We hypothesize that
      administration of potassium citrate to postmenopausal women with osteopenia will delay (or
      will prevent) the weakening of bone mass.

      Postmenopausal women with osteopenia (T score between -1.0 and -2.5) and no history of
      fracture will be randomized to assume KCitr ate or placebo, daily for six months. Primary
      outcomes will be evaluated by measuring markers of bone turnover, which will be measured at
      baseline (before treatment), in the mid-term (3 months) and at the end (6 months).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">September 30, 2017</completion_date>
  <primary_completion_date type="Actual">August 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Serum Level of Carboxyterminal Cross-linked Telopeptide of Type I Collagen (CTX); Over Time, i.e. Baseline, 3 Months, 6 Months.</measure>
    <time_frame>Baseline (T0), 3 months (T3) 6 months (T6)</time_frame>
    <description>Carboxyterminal cross-linked telopeptide of type I collagen (CTX) is a degradation product of the type I collagen; it is considered as a marker of bone resorption. The concentration of CTX (µg/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol.
At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Serum Levels of &quot;Tartrate-resistant Acid Phosphatase 5b Isoenzyme&quot; (TRAcP5b) Over Time, i.e. Baseline, 3 Months, 6 Months.</measure>
    <time_frame>Baseline (T0), 3 months (T3) 6 months (T6)</time_frame>
    <description>Tartrate-resistant acid phosphatase 5b isoenzyme&quot; (TRAcP5b) is a specific product of osteoclasts; it is considered as a marker of bone resorption. The concentration of TRAcP5B (U/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol. At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium Citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Serum Levels of &quot;N-terminal Propeptide of Type I Procollagen&quot; (P1NP) Over Time, i.e. Baseline, 3 Months, 6 Months.</measure>
    <time_frame>Baseline (T0), 3 months (T3) 6 months (T6)</time_frame>
    <description>N-terminal propeptide of type I procollagen&quot; (P1NP) is a product of the conversion of procollagen to collagen; it is considered as a marker of bone formation. The concentration of P1NP (pg/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol. At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Serum Levels of &quot;Bone-specific Alkaline Phosphatase&quot; (BAP) Over Time, i.e. Baseline, 3 Months, 6 Months.</measure>
    <time_frame>Baseline (T0), 3 months (T3) 6 months (T6)</time_frame>
    <description>Bone-specific alkaline phosphatase (BAP) is a specific product of osteoblasts; it is considered as a marker of bone formation. The concentration of BAP (µg/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol. At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Osteopenia</condition>
  <condition>Bone Disease, Metabolic</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potassium citrate Calcium carbonate Vitamin D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Excipients) Calcium carbonate Vitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium citrate</intervention_name>
    <description>Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)</description>
    <arm_group_label>Control group, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>400 IU/die Vitamin D3 daily by mouth</description>
    <arm_group_label>Control group, Placebo</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium carbonate</intervention_name>
    <description>500 mg/die calcium carbonate daily by mouth</description>
    <arm_group_label>Control group, Placebo</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women, more than 5 years post menopause

          -  Osteopenia (T-score &lt; -1 and &gt; -2.5)

          -  Low risk of fracture (FRAX: &lt; 20 major osteoporotic; &lt; 3 hip fracture)

        Exclusion Criteria:

          -  Hyperkalemia

          -  Renal insufficiency

          -  Nephrolithiasis

          -  Use of potassium sparing diuretics

          -  Use of potassium supplements

          -  Use of therapies influencing bone metabolism (e.g. corticosteroids, thiazide
             diuretics, aromatase inhibitors, estrogens)

          -  Use of protonic pump inhibitors

          -  Current or recent use of bisphosphonates (stopped less than three years prior to the
             start of the study)

          -  Gastrointestinal disorders that hamper nutrient absorption;

          -  Mental or psychiatric disorders that preclude the possibility of correctly adhering to
             the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Baldini, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.ior.it/</url>
    <description>Istituto Ortopedico Rizzoli_Home Page</description>
  </link>
  <reference>
    <citation>Arnett TR. Acidosis, hypoxia and bone. Arch Biochem Biophys. 2010 Nov 1;503(1):103-9. doi: 10.1016/j.abb.2010.07.021. Epub 2010 Jul 23. Review.</citation>
    <PMID>20655868</PMID>
  </reference>
  <reference>
    <citation>Lambert H, Frassetto L, Moore JB, Torgerson D, Gannon R, Burckhardt P, Lanham-New S. The effect of supplementation with alkaline potassium salts on bone metabolism: a meta-analysis. Osteoporos Int. 2015 Apr;26(4):1311-8. doi: 10.1007/s00198-014-3006-9. Epub 2015 Jan 9.</citation>
    <PMID>25572045</PMID>
  </reference>
  <reference>
    <citation>Hanley DA, Whiting SJ. Does a high dietary acid content cause bone loss, and can bone loss be prevented with an alkaline diet? J Clin Densitom. 2013 Oct-Dec;16(4):420-5. doi: 10.1016/j.jocd.2013.08.014. Epub 2013 Oct 2. Review.</citation>
    <PMID>24094472</PMID>
  </reference>
  <reference>
    <citation>Jehle S, Hulter HN, Krapf R. Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2013 Jan;98(1):207-17. doi: 10.1210/jc.2012-3099. Epub 2012 Nov 15.</citation>
    <PMID>23162100</PMID>
  </reference>
  <results_reference>
    <citation>Granchi D, Caudarella R, Ripamonti C, Spinnato P, Bazzocchi A, Massa A, Baldini N. Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study. Nutrients. 2018 Sep 12;10(9). pii: E1293. doi: 10.3390/nu10091293.</citation>
    <PMID>30213095</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <results_first_submitted>February 1, 2019</results_first_submitted>
  <results_first_submitted_qc>October 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2019</results_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Rizzoli</investigator_affiliation>
    <investigator_full_name>Nicola Baldini</investigator_full_name>
    <investigator_title>MD, Professor</investigator_title>
  </responsible_party>
  <keyword>potassium citrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All the results will be available &quot;on request&quot;</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.ior.it/en/ricerca-e-innovazione/ethical-committee</doc_url>
      <doc_comment>Study protocol is available on request</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>doi: 10.3390/nu10091293</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://www.mdpi.com/2072-6643/10/9/1293/pdf</doc_url>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02731820/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited among the cohort of post-menopausal women attending to the Radiodiagnostic Unit of Istituto Ortopedico Rizzoli (IOR) from September 2015 to February 2017 to perform the periodic measurements of lumbar (at L2–L4 level) and femoral bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group, Potassium Citrate</title>
          <description>Potassium citrate Calcium carbonate Vitamin D3
Potassium citrate: Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
        </group>
        <group group_id="P2">
          <title>Control Group, Placebo</title>
          <description>Placebo (Excipients) Calcium carbonate Vitamin D3
Placebo: Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group, Potassium Citrate</title>
          <description>Potassium citrate Calcium carbonate Vitamin D3
Potassium citrate: Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
        </group>
        <group group_id="B2">
          <title>Control Group, Placebo</title>
          <description>Placebo (Excipients) Calcium carbonate Vitamin D3
Placebo: Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="4.67"/>
                    <measurement group_id="B2" value="58.2" spread="4.95"/>
                    <measurement group_id="B3" value="59.5" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Osteopenic post-menopausal women</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.6" spread="4.4"/>
                    <measurement group_id="B2" value="22.9" spread="3.8"/>
                    <measurement group_id="B3" value="23.3" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T score (BMD femural neck)</title>
          <description>T-score shows how much bone mineral density (BMD) is higher or lower than the bone density of a healthy 30-year old adult.
According to the World Health Organization (WHO):
T-score of -1.0 or above= normal bone density;
T-score between -1.0 and -2.5 means = osteopenia;
T-score of -2.5 or below = osteoporosis.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.6" spread="0.4"/>
                    <measurement group_id="B2" value="-1.7" spread="0.5"/>
                    <measurement group_id="B3" value="-1.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T score (L2 - L4)</title>
          <description>T-score shows how much bone mineral density (BMD) is higher or lower than the bone density of a healthy 30-year old adult.
According to the World Health Organization (WHO):
T-score of -1.0 or above= normal bone density;
T-score between -1.0 and -2.5 means = osteopenia;
T-score of -2.5 or below = osteoporosis.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.7" spread="0.5"/>
                    <measurement group_id="B2" value="-1.4" spread="0.6"/>
                    <measurement group_id="B3" value="-1.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Major osteoporotic risk</title>
          <description>Ten-year percentage probability of a major osteoporotic fracture (spine, forearm, hip or shoulder fracture) calculated according to “Fracture risk assessment tool (FRAX™)” (available on www.sheffield.ac.uk/FRAX/tool.aspx?lang=en).</description>
          <units>% (percentage probability)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="3.4"/>
                    <measurement group_id="B2" value="4.8" spread="1.5"/>
                    <measurement group_id="B3" value="5.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minor osteoporotic risk</title>
          <description>Ten-year percentage probability of hip fracture calculated according to “Fracture risk assessment tool (FRAX™)” (available on www.sheffield.ac.uk/FRAX/tool.aspx?lang=en).</description>
          <units>% (percentage probability)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="0.8"/>
                    <measurement group_id="B2" value="1.0" spread="0.5"/>
                    <measurement group_id="B3" value="1.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pH (24h urine)</title>
          <description>Reference value: 5.50 - 7.00</description>
          <units>pH value</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.13" lower_limit="5.28" upper_limit="7.00"/>
                    <measurement group_id="B2" value="6.03" lower_limit="4.65" upper_limit="7.14"/>
                    <measurement group_id="B3" value="6.08" lower_limit="4.65" upper_limit="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pH (fasting-morning urine)</title>
          <description>Measure Description: Reference value 5.50 - 7.00</description>
          <units>pH value</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.13" lower_limit="4.97" upper_limit="7.36"/>
                    <measurement group_id="B2" value="5.87" lower_limit="4.59" upper_limit="7.05"/>
                    <measurement group_id="B3" value="6.00" lower_limit="4.59" upper_limit="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Potassium (24h urine)</title>
          <description>Reference value: 50–100 mEq day−1</description>
          <units>milliequivalent day−1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.60" spread="14.97"/>
                    <measurement group_id="B2" value="30.40" spread="12.98"/>
                    <measurement group_id="B3" value="29.50" spread="13.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Citrate (24h urine)</title>
          <description>Reference value: &gt;3.3 mmol day−1</description>
          <units>mmol day−1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.97" spread="1.68"/>
                    <measurement group_id="B2" value="3.50" spread="1.74"/>
                    <measurement group_id="B3" value="3.24" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Citrate (fasting-morning urine)</title>
          <description>Reference value: &gt; 0.3 mol mol−1 (Citrate/Creatinine)</description>
          <units>mol mol−1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.77" spread="1.39"/>
                    <measurement group_id="B2" value="3.40" spread="2.39"/>
                    <measurement group_id="B3" value="3.09" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Serum Level of Carboxyterminal Cross-linked Telopeptide of Type I Collagen (CTX); Over Time, i.e. Baseline, 3 Months, 6 Months.</title>
        <description>Carboxyterminal cross-linked telopeptide of type I collagen (CTX) is a degradation product of the type I collagen; it is considered as a marker of bone resorption. The concentration of CTX (µg/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol.
At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
        <time_frame>Baseline (T0), 3 months (T3) 6 months (T6)</time_frame>
        <population>3/20 patients in the Treatment group did not complete the follow up (n= 1 re-evaluation of the inclusion criteria; n=1 gastritis; n=1 total hip arthroplasty).
2/20 patients in the Placebo group did not complete the follow up (n=2 persistent constipation)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group, Potassium Citrate</title>
            <description>Potassium citrate Calcium carbonate Vitamin D3
Potassium citrate: Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Control Group, Placebo</title>
            <description>Placebo (Excipients) Calcium carbonate Vitamin D3
Placebo: Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Level of Carboxyterminal Cross-linked Telopeptide of Type I Collagen (CTX); Over Time, i.e. Baseline, 3 Months, 6 Months.</title>
          <description>Carboxyterminal cross-linked telopeptide of type I collagen (CTX) is a degradation product of the type I collagen; it is considered as a marker of bone resorption. The concentration of CTX (µg/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol.
At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
          <population>3/20 patients in the Treatment group did not complete the follow up (n= 1 re-evaluation of the inclusion criteria; n=1 gastritis; n=1 total hip arthroplasty).
2/20 patients in the Placebo group did not complete the follow up (n=2 persistent constipation)</population>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (T0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.08"/>
                    <measurement group_id="O2" value="0.64" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (T3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.08"/>
                    <measurement group_id="O2" value="0.56" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (T6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.08"/>
                    <measurement group_id="O2" value="0.54" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T3 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T6 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T6 vs T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Placebo: T3 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Placebo: T6 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Placebo: T6 vs T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.139</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.967</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.446</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.869</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Serum Levels of &quot;Tartrate-resistant Acid Phosphatase 5b Isoenzyme&quot; (TRAcP5b) Over Time, i.e. Baseline, 3 Months, 6 Months.</title>
        <description>Tartrate-resistant acid phosphatase 5b isoenzyme&quot; (TRAcP5b) is a specific product of osteoclasts; it is considered as a marker of bone resorption. The concentration of TRAcP5B (U/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol. At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium Citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
        <time_frame>Baseline (T0), 3 months (T3) 6 months (T6)</time_frame>
        <population>3/20 patients in the Treatment group did not complete the follow up (n= 1 re-evaluation of the inclusion criteria; n=1 gastritis; n=1 total hip arthroplasty).
2/20 patients in the Placebo group did not complete the follow up (n=2 persistent constipation)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group, Potassium Citrate</title>
            <description>Potassium citrate Calcium carbonate Vitamin D3
Potassium citrate: Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Control Group, Placebo</title>
            <description>Placebo (Excipients) Calcium carbonate Vitamin D3
Placebo: Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Levels of &quot;Tartrate-resistant Acid Phosphatase 5b Isoenzyme&quot; (TRAcP5b) Over Time, i.e. Baseline, 3 Months, 6 Months.</title>
          <description>Tartrate-resistant acid phosphatase 5b isoenzyme&quot; (TRAcP5b) is a specific product of osteoclasts; it is considered as a marker of bone resorption. The concentration of TRAcP5B (U/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol. At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium Citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
          <population>3/20 patients in the Treatment group did not complete the follow up (n= 1 re-evaluation of the inclusion criteria; n=1 gastritis; n=1 total hip arthroplasty).
2/20 patients in the Placebo group did not complete the follow up (n=2 persistent constipation)</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (T0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.20"/>
                    <measurement group_id="O2" value="2.64" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (T3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="0.27"/>
                    <measurement group_id="O2" value="2.85" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (T6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="0.29"/>
                    <measurement group_id="O2" value="2.25" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T3 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.954</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T6 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.798</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T6 vs T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.377</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Placebo: T3 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.886</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Placebo: T6 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Placebo: T6 vs T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.343</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.859</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Serum Levels of &quot;N-terminal Propeptide of Type I Procollagen&quot; (P1NP) Over Time, i.e. Baseline, 3 Months, 6 Months.</title>
        <description>N-terminal propeptide of type I procollagen&quot; (P1NP) is a product of the conversion of procollagen to collagen; it is considered as a marker of bone formation. The concentration of P1NP (pg/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol. At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
        <time_frame>Baseline (T0), 3 months (T3) 6 months (T6)</time_frame>
        <population>3/20 patients in the Treatment group did not complete the follow up (n= 1 re-evaluation of the inclusion criteria; n=1 gastritis; n=1 total hip arthroplasty).
2/20 patients in the Placebo group did not complete the follow up (n=2 persistent constipation)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group, Potassium Citrate</title>
            <description>Potassium citrate Calcium carbonate Vitamin D3
Potassium citrate: Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Control Group, Placebo</title>
            <description>Placebo (Excipients) Calcium carbonate Vitamin D3
Placebo: Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Levels of &quot;N-terminal Propeptide of Type I Procollagen&quot; (P1NP) Over Time, i.e. Baseline, 3 Months, 6 Months.</title>
          <description>N-terminal propeptide of type I procollagen&quot; (P1NP) is a product of the conversion of procollagen to collagen; it is considered as a marker of bone formation. The concentration of P1NP (pg/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol. At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
          <population>3/20 patients in the Treatment group did not complete the follow up (n= 1 re-evaluation of the inclusion criteria; n=1 gastritis; n=1 total hip arthroplasty).
2/20 patients in the Placebo group did not complete the follow up (n=2 persistent constipation)</population>
          <units>pg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (T0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.45" spread="1.48"/>
                    <measurement group_id="O2" value="18.82" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (T3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.24" spread="1.60"/>
                    <measurement group_id="O2" value="18.39" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (T6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.97" spread="1.51"/>
                    <measurement group_id="O2" value="16.77" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T3 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.213</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T6 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T6 vs T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.234</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Placebo: T3 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.370</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Placebo: T6 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.176</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Placebo: T6 vs T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.139</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.551</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.466</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Serum Levels of &quot;Bone-specific Alkaline Phosphatase&quot; (BAP) Over Time, i.e. Baseline, 3 Months, 6 Months.</title>
        <description>Bone-specific alkaline phosphatase (BAP) is a specific product of osteoblasts; it is considered as a marker of bone formation. The concentration of BAP (µg/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol. At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
        <time_frame>Baseline (T0), 3 months (T3) 6 months (T6)</time_frame>
        <population>3/20 patients in the Treatment group did not complete the follow up (n= 1 re-evaluation of the inclusion criteria; n=1 gastritis; n=1 total hip arthroplasty).
2/20 patients in the Placebo group did not complete the follow up (n=2 persistent constipation)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group, Potassium Citrate</title>
            <description>Potassium citrate Calcium carbonate Vitamin D3
Potassium citrate: Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Control Group, Placebo</title>
            <description>Placebo (Excipients) Calcium carbonate Vitamin D3
Placebo: Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Levels of &quot;Bone-specific Alkaline Phosphatase&quot; (BAP) Over Time, i.e. Baseline, 3 Months, 6 Months.</title>
          <description>Bone-specific alkaline phosphatase (BAP) is a specific product of osteoblasts; it is considered as a marker of bone formation. The concentration of BAP (µg/L) will be measured at T0, T3, and T6 on serum samples (fasting morning samples) using commercially available reagents and following the manufacturer's protocol. At the end of the study, the results will be aggregated as mean ± standard of the mean, median and min-max range. Data will be statistically analyzed in order to compare the activity of Potassium citrate versus Placebo (unpaired analysis) and to evaluate the effect of Potassium Citrate and Placebo over time (paired analysis).
Differences will be considered to be statistically significant for p-value &lt;0.05.</description>
          <population>3/20 patients in the Treatment group did not complete the follow up (n= 1 re-evaluation of the inclusion criteria; n=1 gastritis; n=1 total hip arthroplasty).
2/20 patients in the Placebo group did not complete the follow up (n=2 persistent constipation)</population>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (T0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.89" spread="1.67"/>
                    <measurement group_id="O2" value="20.36" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (T3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.81" spread="1.67"/>
                    <measurement group_id="O2" value="18.27" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (T6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.83" spread="1.37"/>
                    <measurement group_id="O2" value="15.79" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T3 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T6 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T6 vs T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Placebo: T3 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T6 vs T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis within the group to evaluate the effect of Potassium Citrate: T6 vs T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.458</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.434</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent comparison (unpaired analysis) between Potassium Citrate and Placebo at T6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.555</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded at 3 months and 6 months</time_frame>
      <desc>Gastrointestinal disorders</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Potassium citrate Calcium carbonate Vitamin D3
Potassium citrate: Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
        </group>
        <group group_id="E2">
          <title>Control Group, Placebo</title>
          <description>Placebo (Excipients) Calcium carbonate Vitamin D3
Placebo: Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Vitamin D3: 400 IU/die Vitamin D3 daily by mouth
Calcium carbonate: 500 mg/die calcium carbonate daily by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Istituto Ortopedico Rizzoli</organization>
      <phone>+39 051.6366392</phone>
      <email>ctc@ior.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

